Appendix Cancer Systemic Chemotherapy
Appendiceal Adenocarcinoma Systemic Chemotherapy
Resources, Referrals, Research and Support
Appendix Cancer Systemic Chemotherapy
Once thought to be ineffective for the treatment of Appendix Cancer, and Pseudomyxoma Peritonei, systemic chemotherapy treatment has become common during the past decade due to the development of several new colorectal cancer therapies.
Several systemic chemotherapies (many listed below) have become treatment options for Appendix cancer, pseudomyxoma peritonei patients and other PC and PSM patients.Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
HIPEC, a chemotherapy treatment delivered directly into the peritoneal cavity, is listed on its own link on this website.
Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
Is systemic chemotherapy an appropriate treatment for appendix cancer and peritoneal surface malignancies?
Participants in "Chemo Pals" are PC, PSM, Pseudomyxoma Peritonei and Appendix Cancer patients who exchange information regarding the particular chemotherapy (ies) utilized, including results of their treatment regimens.
Tips for Coping with Xeloda Side Effects
By Pal Patient, Mike, UK and USA
(in this photo, Mike "models" Xeloda tablets)
About Pal member Mike:
Mike is an Appendiceal Cancer patient and is a “veteran” of CRS with HIPEC.
He is not cancer free; therefore his current medical treatment plan includes taking the oral chemotherapy tablet, Xeloda.
Mike is the married father of an active teen and works full time in a job he enjoys. When not working, he and his family enjoy “escaping” to their cabin in the woods where Mike enjoys his favorite hobby of fishing.
He is a graduate of University of Oxford and holds a PhD.
Mike is an active member of the PMP Pals’ Network and serves as a Pal Mentor to other Pals receiving the Xeloda treatment protocol. Today he shares a few helpful suggestions for fellow patients receiving chemotherapy:
Know your limits
Be aware of when you begin feel fatigue, and immediately set aside some time for a brief nap and/or to rest.
Speak up to friends and family
Let your co workers, colleagues and family know when you begin to feel tired.
I have learned that if I don’t advise colleagues of my physical limits, they assume I am “normal” and healthy and expect me to work fourteen hours a day. I have learned that it’s best to be frank and advise my co workers of my limitations during chemotherapy treatment
Set aside time for R&R
Find new ways to set aside time for rest and recreation. Many cancer patients continue to work full time while receiving chemotherapy. If you are working, you may need to adjust your usual routine to make time for an extra nap or simply to enjoy a bit of time off during a day when you are feeling well.
For example, last week, while traveling for work and conducting training seminars every day, I set aside the usual evening entertainment of dinners out with colleagues in order to turn in early and get a good night’s sleep!.
Eat nutritious foods
Quality proteins and carbohydrates are important in helping to protect you against anemia. I enjoy camping out at my cabin during my weekends off, and enjoy a 16 oz. steak and beans over an open fire in the woods - it doesn't get any better than that!
Adopt a positive attitude
A positive attitude goes without saying. I'm not especially religious and I don’t ask why I got I have cancer; I have it and therefore I deal with it. I am not cancer free (and that is why I am receiving chemotherapy) but I don’t dwell on that fact…as a matter of fact, I am too busy with work and family life to worry about it!
Visit us on the web at www.pmppals.org
We have HOPE for YOU!
Articles posted in PMP Pals and on www.pmppals.org are written from the perspective of patients and family caregivers and are not intended to substitute for licensed, professional legal or medical advice. Each patient’s case is unique; therefore consult with a licensed professional regarding your specific needs.
Copyright © 2013 by PMP Pals’ Network Publishing.
All rights reserved. Todos derechos reservados.
The PMP Pals' Network is an HONcode certified website
How to Prepare for Chemotherapy
Xeloda
Xeloda tablets
Cancer Survival After Chemotherapy
Photo by Mark Harmel
Researchers Identify Genetic Profile That Predicts Cancer Survival After Chemotherapy
Source: Time Health & Family, Alexandra Sifferlin , April 17, 2013
Appendix Cancer Patients Lead Active Lives on Chemo!
Our Pal, Andy, participates in a bike marathon while on chemotherapy!
Neuropathy
Definition and Treatments for Neuropathy from Chemotherapy
Source: Sheryl Ness, Mayo Clinic Nurse Educator
MD Anderson Offers Trial Program to Combat Neuropathy
Source: MD Anderson
Source: Sheryl Ness, Mayo Clinic Nurse Educator
MD Anderson Offers Trial Program to Combat Neuropathy
Source: MD Anderson
Cymbalta May Relieve Neuropathy Pain
Cymbalta May Relieve Chemo-Induced Pain, Tingling
Antidepressant May Work Against Chemo-Related Peripheral Neuropathy
Source: WebMD 06.04.12
Chemotherapies Differ Among Patients
Chemo Questions and Resources
How to Prevent Infections for Chemotherapy Patients
Prevent Infections in Cancer Patients
Source: CDC
Prevencion de infecciones en pacientes con cancer
Source: CDC
FUDR
Floxuridine (FUDR) is used to treat patients diagnosed with colorectal cancers. FUDR is injected into a patient’s vein or artery via an infusion pump.
Appendix Cancer patients lead active lives during chemotherapy!
Our Pal, Mike, catches "the big one" while taking Xeloda!
Systemic Chemotherapy Studies for Appendiceal Cancer and PMP
Phase II Study Tests Effectiveness of Systemic Chemo for Pseudomyxoma Peritonei
Source: Christies Hospital, Manchester UK, Aug 2008
Pseudomyxoma Peritonei Treatment with Avastin and Xeloda
Source: Cancer Bio Ther (Austria and China) Aug 2009
Pseudomyxoma Peritonei Treatment with Adjuvant Chemotherapy
Source: World Journal of Surgical Oncology 2008
Systemic Chemotherapy for Appendix Cancer Prior to CRS HIPEC
Dr Paul Sugarbaker
Systemic Chemotherapy Prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival.
Authors: Bijelic L, Kumar AS, Stuart OA, Sugarbaker PH.
Source: Section of Surgical Oncology, Department of Surgery, Washington Hospital Center, 110 Irving Street, Washington, DC 20010, USA.
Abstract
Background and Objectives.
Systemic chemotherapy administered prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mucinous adenocarcinoma of appendiceal origin (PMCA) is associated with a significant rate of histological response. The impact of preoperative systemic chemotherapy (PSC) on intraperitoneal tumor burden, completeness of cytoreduction, and perioperative complications is unknown.
Methods.
We analyzed prospectively collected data from our HIPEC database. Thirty-four patients with PMCA were prospectively recruited and treated with PSC. Perioperative variables and survival in this group of patients were compared against 24 patients with PMCA who did not receive PSC.
Results.
Ten of 34 patients (29%) receiving PSC had a complete or near complete histological response. Patients receiving PSC had a lower peritoneal carcinomatosis index, required fewer peritonectomies and visceral resections, and achieved complete cytoreduction more frequently compared to patients with no preoperative chemotherapy. The incidence of perioperative complications and survival were not significantly different between the two groups.
However, patients with complete histological response had better overall survival compared to patients without complete response.
Conclusions. Preoperative systemic chemotherapy in appendix-originated PMCA is associated with a significant rate of histological response which may reduce the tumor burden, facilitate less aggressive and more complete CRS, and improve short-term survival in patients with a significant histological response.
PMID:22899903 [PubMed] July 2012
Study of Perioperative Systemic Chemotherapy
Dr Perry Shen, WFU
Perioperative Systemic Chemotherapy for Appendiceal Cancer treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Source: Blackham AU, Swett K, Sirintrapun J, Bergman S, Eng C, Stewart JH, Shen P, Levine EA, Wake Forest University
Background: The role of perioperative systemic chemotherapy (pSC) in conjunction with cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS/HIPEC) for treating appendiceal cancer is unknown.
Methods: A retrospective review of patients from two high volume centers (1999-2010) who received pSC within 3 months of CS/HIPEC for appendiceal peritoneal surface disease (PSD). A match-controlled analysis of patients with low grade histology was performed. All patients with high grade tumors were analyzed based on the use of pSC.
Results: 22 patients with low grade PSD who underwent CS/HIPEC and received pSC were matched by resection status, age and lymph node status to patients who did not received pSC. Median progression-free survival (PFS) was 29.5 months for patients treated with pSC compared to 37.0 months treated without pSC (p=0.18). There was a non-significant trend toward improved median overall survival (OS) with the use of pSC (107 vs 72 months, p=0.46).
CS/HIPEC was performed on 109 patients with high grade PDS: 70 were treated with pSC, while 39 were not. In comparing these two groups, there were no differences in lymph node status (p=1.0), resection status (p=0.84), age (p=0.71) or prior debulking surgery (p=0.68). The median OS (22.1 vs 19.6 months, p=0.74) and median PFS (10.9 vs 7.0 months, p=0.47) were similar in patients who received pSC compared to those treated without pSC. Progression while on preoperative SC was seen in 17% of patients, while 8% had a partial response and 73% had stable disease. Recurrence or progression while on adjuvant SC was seen in 25% of patients. The use of adjuvant SC resulted in longer PFS (13.6 months) compared to preoperative SC (6.8 months, p<0.01) and no pSC (7.0 months, p=0.03); however, it only trended toward better OS compared to preoperative SC (36.4 vs 16.0 months, p=0.06) and to no pSC (36.4 vs 19.6 months, p=0.14).
Conclusions: These results suggest that there is a limited role for perioperative SC in low grade appendiceal PSD treated with CS/HIPEC. In contrast, patients with high grade appendiceal PSD appear to benefit from adjuvant SC.
Presented at SSO, March 2013
Posted on www.pmppals.org with permission of Dr Perry Shen
Copyright © 2013 by Wake Forest University
Is Chemotherapy Helpful for Treating Pseudomyxoma Peritonei?
Is Chemotherapy Helpful for Treating Pseudomyxoma Peritonei?
This week, Pal Caregiver, Pat from the US, poses this question the PMP Pals’ Network:
“My husband’s doctor says he should begin receiving systemic chemotherapy to treat his advancing case of Pseudomyxoma Peritonei. He has already had surgery, but the cancer continues to spread.
Should my husband agree to receive chemotherapy or not?”
GG responds: “First of all, as with any medical scenario, whether or not a patient commences chemotherapy is a topic that one should explore thoroughly with one’s personal physician and/or team of healthcare providers.
Each patient is unique. Pseudomyxoma Peritonei is not "one size fits all" disease. You are asking whether chemotherapy is really necessary for your husband. How he makes this decision depends on the pathology, histology, symptoms and aggressiveness of his particular case.
Pseudomyxoma Peritonei is generally treated by surgical oncologists with specific surgery, which may or may not include HIPEC (Hyperthermic Interperitoneal Chemotherapy.)
In years past, systemic chemotherapy was thought to be unsuccessful for patients diagnosed with Pseudomyxoma Peritonei. However, during the past decade, due to the availability of more chemotherapies developed for the treatment of colon/colorectal cancers, some physicians are recommending systemic chemotherapy for specific Pseudomyxoma Peritonei patients.
When preparing to consult with the oncologist, the patient should prepare a concise,
detailed list of questions and should have the following reports in hand:
Pathology report(s) from surgery, biopsy, paracentesis, or whatever is applicable,
Laboratory test(s) for tumor markers specifically the current CEA and CA 19 9 markers,
The radiologist’s written report from the patient’s current CT or MRI scans.
These are among the questions for consideration when meeting w/your oncologist:
Why is systemic chemotherapy being proposed?
Are other treatment options available?
What is the extent and location (i.e. on the small intestine) of remaining visible disease, per recent surgery or CT scan(s)?
What type of chemotherapy(ies) does the oncologist or surgeon recommend?
Why is s/he recommending this particular chemotherapy regimen for this particular diagnosis?
What data justifies the particular chemotherapy that the oncologist is proposing?
How does the oncologist anticipate this particular chemotherapy will help the patient?
What are the known side effects of this chemotherapy?”
After your husband has heard the answers to these questions, he will be in a better position to determine whether chemotherapy may be helpful for his particular case.
For additional resources regarding the efficacy of systemic chemotherapy, you are invited to participate in the PMP Pals’ Chemo Resource Group via www.pmppals.org
“Chemo Pals” is one of the largest and most active resource and support groups within the PMP Pals Network.
For more information see the Chemotherapy link at www.pmppals.org
The PMP Pals’ Network does not provide medical or legal advice.
Patients should seek the advice of their own professional healthcare providers.
Copyright © 2013 by PMP Pals’ Network/All rights reserved. Todos derechos reservados.
This article may not be reproduced without written permission from the PMP Pals’ Network.
Analysis of Chemotherapy Effectiveness
Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity
Yi-Chiung Hsu, Hsuan-Yu Chen, Shinsheng Yuan, Sung-Liang Yu, Chia-Hung Lin, Guani Wu, Pan-Chyr Yang and Ker-Chau Li
BMC Medicine 2013, 11:106 doi:10.1186/1741-7015-11-106
Published: 16 April 2013
Abstract (provisional)
Background
Chemosensitivity and tumor metastasis are two primary issues in cancer management. Cancer cells often exhibit a wide range of sensitivity to anti-cancer compounds. To gain insight on the genetic mechanism of drug sensitivity, one powerful approach is to employ the panel of 60 human cancer cell lines developed by the National Cancer Institute (NCI). Cancer cells also show a broad range of invasion ability. However, a genome-wide portrait on the contributing molecular factors to invasion heterogeneity is lacking.
Methods
Our lab performed an invasion assay on the NCI-60 panel. We identified invasion-associated (IA) genes by correlating our invasion profiling data with the Affymetrix gene expression data on NCI-60. We then employed the recently released chemosensitivity data of 99 anti-cancer drugs of known mechanism to investigate the gene-drug correlation, focusing on the IA genes. Afterwards, we collected data from four independent drug-testing experiments to validate our findings on compound response prediction. Finally, we obtained published clinical and molecular data from two recent adjuvant chemotherapy cohorts, one on lung cancer and one on breast cancer, to test the performance of our gene signature for patient outcome prediction.
Results
First, we found 633 IA genes from the invasion-gene expression correlation study. Then, for each of the 99 drugs, we obtained a subset of IA genes whose expression levels correlated with drug-sensitivity profiles. We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib. This eight-gene signature (derived from NCI-60) for chemosensitivity prediction was validated by a total of 107 independent drug tests on 78 tumor cell lines, most of which were outside of the NCI-60 panel. The eight-gene signature predicted relapse-free survival for the lung and breast cancer patients (log-rank P = 0.0263; 0.00021). Multivariate Cox regression yielded a hazard ratio of our signature of 5.33 (95% CI = 1.76 to 16.1) and 1.81 (95% CI = 1.19 to 2.76) respectively. The eight-gene signature features the cancer hallmark epidermal growth factor receptor (EGFR) and genes involved in cell adhesion, migration, invasion, tumor growth and progression.
Conclusions
Our study sheds light on the intricate three-way interplay among gene expression, invasion and compound-sensitivity. We report the finding of a unique signature that predicts chemotherapy survival for both lung and breast cancer. Augmenting the NCI-60 model with in vitro characterization of important phenotype-like invasion potential is a cost-effective approach to power the genomic chemosensitivity analysis.
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
Life on Chemotherapy: Elaine is on the go!
Elaine enjoys horseback riding in between chemotherapy sessions!
Health Insurance for Chemotherapy Patients
Financial Aid for Chemotherapy
My Senior Mother Can’t Afford Chemo; Is There Help?
TGV from the USA asks:
“My 77 year old widowed mother is undergoing her second round of chemo treatment for Primary Peritoneal Cancer. She is on a fixed low-income and her copayments for chemotherapy
She is scheduled for an infusion today and was told it would cost her copayment is $1600. This is exorbitant! She lives in California. Her small savings are quickly dwindling. Are there programs/foundations that can provide financial assistance for her medical care?”
GG answers from the Pals’ desk:
We offer the following suggestions to help your mother in obtaining assistance in the payment of copayments for her chemotherapy treatment.
Contact the agencies listed here under the Chemotherapy Assistance section of our Financial Benefits page at www.pmppals.org
Check for any additional financial aid your mother may be eligible by taking the Benefits Check Up, also listed on our Financial Benefits page at www.pmppals.org
For specific assistance in California, see the Health Consumer Alliance and the California Healthcare Foundation resources listed here on our Health Insurance page at www.pmppals.org
A variety of healthcare assistance programs for Californians are listed under this page.
Apply to the local State of California Medicaid office for additional assistance in paying for costs not covered by Medicare.
Lastly, review the wide variety of Senior Services listed via www.pmppals.org
Articles posted in PMP Pals and on www.pmppals.org are written from the perspectives of patients and their families and are not intended to substitute for licensed, professional legal or medical advice. Each patient is unique and should seek specific counsel from their own licensed healthcare professional. Copyright © 2012 by PMP Pals Publishing. All rights reserved.
Today's Article of Interest...
ASCO Addresses Chemotherapy Shortage
Nutrition
Does Food Interfere with the Effectiveness of Chemotherapy?
Appendix cancer patient, KR, from the USA, will begin systemic chemotherapy treatment, using Folfiri, within a few days. She submitted the following question to the PMP Pals’ Network:
“I read on the internet that some foods may interfere with the effectiveness of chemotherapy. Which foods should I avoid?”
PMP Pals replies:
“We are not aware of any foods that interfere with the effectiveness of chemotherapy.
1. There are a wide variety of chemotherapies. When seeking information, be sure that the information you obtain is specific to the chemotherapy prescribed to you, in this case Folfiri.
2. Always seek advice of this nature from your oncologist and your pharmacist.
3. A helpful source of information, specific to your question is the advice nurse available via the manufacturer/producer of nearly any chemo prescribed for you. The major pharmaceutical companies (e.g. Roche, Teva, etc.) provide telephone advice nurses to answer questions from patients.
The PMP Pals' Network does not endorse the use of online "chat rooms", "message boards", Facebook, etc. for obtaining detailed medical information. Specific medical information should be directed to one's licensed, professional healthcare team.
Dr Letai Explains Why Chemotherapy May or May Not Be Effective
Dr Anthony Letai
Why is chemotherapy effective for some cases, but not for others?
Dr Anthony Letai addresses this question in today's issue of the NCI Bulletin!
Source: NCI Bulletin 01.08.13
Effects of Chemotherapy for Advanced Colorectal Cancer
Patients' Expectations about Effects of Chemotherapy for Advanced Cancer
Jane C. Weeks, M.D., Paul J. Catalano, Sc.D., Angel Cronin, M.S., Matthew D. Finkelman, Ph.D., Jennifer W. Mack, M.D., M.P.H., Nancy L. Keating, M.D., M.P.H., and Deborah Schrag, M.D., M.P.H.
*Source: N Engl J Med 2012; 367:1616-1625October 25, 2012DOI: 10.1056/NEJMoa1204410
*“BACKGROUND
Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative.
METHODS
We studied 1193 patients participating in the Cancer Care Outcomes Research and Surveillance (CanCORS) study (a national, prospective, observational cohort study) who were alive 4 months after diagnosis and received chemotherapy for newly diagnosed metastatic (stage IV) lung or colorectal cancer. We sought to characterize the prevalence of the expectation that chemotherapy might be curative and to identify the clinical, sociodemographic, and health-system factors associated with this expectation. Data were obtained from a patient survey by professional interviewers in addition to a comprehensive review of medical records.
RESULTS
Overall, 69% of patients with lung cancer and 81% of those with colorectal cancer did not report understanding that chemotherapy was not at all likely to cure their cancer. In multivariable logistic regression, the risk of reporting inaccurate beliefs about chemotherapy was higher among patients with colorectal cancer, as compared with those with lung cancer (odds ratio, 1.75; 95% confidence interval [CI], 1.29 to 2.37); among nonwhite and Hispanic patients, as compared with non-Hispanic white patients (odds ratio for Hispanic patients, 2.82; 95% CI, 1.51 to 5.27; odds ratio for black patients, 2.93; 95% CI, 1.80 to 4.78); and among patients who rated their communication with their physician very favorably, as compared with less favorably (odds ratio for highest third vs. lowest third, 1.90; 95% CI, 1.33 to 2.72). Educational level, functional status, and the patient's role in decision making were not associated with such inaccurate beliefs about chemotherapy.
CONCLUSIONS
Many patients receiving chemotherapy for incurable cancers may not understand that chemotherapy is unlikely to be curative, which could compromise their ability to make informed treatment decisions that are consonant with their preferences. Physicians may be able to improve patients' understanding, but this may come at the cost of patients' satisfaction with them. (Funded by the National Cancer Institute and others.)
Supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center (U01 CA093344) and the NCI-supported Primary Data Collection and Research Centers, Dana–Farber Cancer Institute/Cancer Research Network (U01 CA093332), Harvard Medical School/Northern California Cancer Center (U01 CA093324, RAND/UCLA U01 CA093348), University of Alabama at Birmingham (U01 CA093329), University of Iowa (U01 CA093339), and University of North Carolina (U01 CA093326); and by a Department of Veterans Affairs grant to the Durham Veterans Affairs Medical Center (CRS 02-164).
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
SOURCE INFORMATION
From the Departments of Medical Oncology (J.C.W., A.C., D.S.), Biostatistics and Computational Biology (P.J.C.), and Pediatric Oncology (J.W.M.), Dana–Farber Cancer Institute, the Department of Public Health and Community Service, Tufts University School “of Dental Medicine (M.D.F.), and the Department of Medicine, Brigham and Women's Hospital, and the Department of Health Care Policy, Harvard Medical School (N.L.K.) — all in Boston.
Address reprint requests to Dr. Weeks at the Dana–Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, or at jane_weeks@dfci.harvard.edu.
Access this article: Subscribe to NEJM | Purchase this article”
Chemotherapy for Unresectable Appendiceal Cancer
Systemic chemotherapy in the setting of unresectable Appendiceal Epithelial Neoplasms (AEN).
Source: J Clin Oncol 30, 2012 (suppl 4; abstr 568)
ASCO Abstract # 568
Author(s): Cathy Eng, Aaron Udell Blackham, Michael J. Overman, Keith F. Fournier, Richard E. Royal, Prianka Gajula, Edward Allen Levine, Robert A. Wolff, Paul F. Mansfield; University of Texas M.D. Anderson Cancer Center, Houston, TX; Wake Forest School of Medicine, Winston-Salem, NC
In brief: AEN is a malignancy including both indolent well-differentiated and highly aggressive signet ring carcinoma. Optimal therapy is believed to be cytoreductive surgery (CRS) followed by heated intraperitoneal chemotherapy (HIPEC).The purpose of this study is to compare SC regimens in treatment-naïve surgically unresectable AEN pts.
Chemotherapy(ies)* for Unresectable Appendix Cancer:659 patients studied btwn 2005 and 2009: 5FU,Folfiri,Folfox
Conclusions: In the treatment of surgically unresectable AEN, combination chemotherapy resulted in improved PFS vs. single agent 5-FU. Quality of life analysis will be reported at a later date. Randomized prospective analysis should be considered.
Source: J Clin Oncol 30, 2012 (suppl 4; abstr 568)
ASCO Abstract # 568
Author(s): Cathy Eng, Aaron Udell Blackham, Michael J. Overman, Keith F. Fournier, Richard E. Royal, Prianka Gajula, Edward Allen Levine, Robert A. Wolff, Paul F. Mansfield; University of Texas M.D. Anderson Cancer Center, Houston, TX; Wake Forest School of Medicine, Winston-Salem, NC
In brief: AEN is a malignancy including both indolent well-differentiated and highly aggressive signet ring carcinoma. Optimal therapy is believed to be cytoreductive surgery (CRS) followed by heated intraperitoneal chemotherapy (HIPEC).The purpose of this study is to compare SC regimens in treatment-naïve surgically unresectable AEN pts.
Chemotherapy(ies)* for Unresectable Appendix Cancer:659 patients studied btwn 2005 and 2009: 5FU,Folfiri,Folfox
Conclusions: In the treatment of surgically unresectable AEN, combination chemotherapy resulted in improved PFS vs. single agent 5-FU. Quality of life analysis will be reported at a later date. Randomized prospective analysis should be considered.
Systemic Chemo Therapy for Advanced Appendix Cancer
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the National Comprehensive Cancer Network (NCCN) database.
ASCO Abstract No:562
Source:J Clin Oncol 30, 2012 (suppl 4; abstr 562)Author(s): Mohamedtaki Abdulaziz Tejani, Anna ter Veer, Dana Milne, Rebecca Ottsesen, Tanios S. Bekaii-Saab, Al Bowen Benson, Deborah Schrag, Stephen Shibata, John Michael Skibber, Martin R. Weiser, Neal W. Wilkinson, Steven J. Cohen; University of Rochester Medical Center, Rochester, NY; City of Hope, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; The Ohio State University Medical Center, Columbus, OH; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA
Abstract:
Background: Appendiceal neoplasms are rare and represent 1% of intestinal tumors in the United States. The role and efficacy of modern systemic therapy in advanced appendiceal adenocarcinoma has not been established.
Methods: Patients with recurrent or metastatic appendiceal adenocarcinoma in the NCCN Colorectal Database (2005-2010) were analyzed. Study objectives were to describe and evaluate the efficacy of systemic therapy and investigate relationships with clinicopathologic features. Cox regression analysis was performed to identify predictors of PFS and OS. The hazard ratio and 95% CI from Cox models and median PFS and OS from Kaplan-Meier curves were reported.
Results: Of 177 patients with advanced appendiceal carcinoma, 81 (46%) received systemic therapy for measurable disease and are the focus of this report (patients undergoing IP chemotherapy excluded).
Patient/tumor characteristics: median age 50 (range 20-82), ECOG PS 0/1 (67%/22%), mucinous/non-mucinous (44 %/ 51%), 91% peritoneal and 15% liver metastases. 70% of patients had primary surgical debulking.
Common chemotherapy regimens included FOLFOX with or without bevacizumab (n=30 and n=28), FOLFIRI (n=11), and single-agent fluoropyrimidine (n=7). Among 70 patients with a recorded best response, the response rate (RR) was 46% with 31% stable disease. Median PFS was 1.0 year (95% CI: 0.7-1.9) and OS was 2.1 years (95% CI: 1.7-2.6). Patients with non-mucinous histology, high grade tumors and non-debulking surgery had worse PFS and OS.
Conclusions: Treatment of advanced appendiceal adenocarcinoma at NCCN centers commonly incorporates agents utilized for colorectal cancer. RR, PFS and OS are comparable to those achieved in the treatment of metastatic CRC and support routine use of these regimens in clinical practice. Poor prognostic factors include non-mucinous histology, high grade and not undergoing debulking surgery.
Today's Article of Interest...
Researchers discover new mechanism behind resistance to cancer treatment that could lead to better therapies Source: Fred Hutchinson Cancer Center, 08.05.12
Avastin
Determining Which Bowel Cancer Patients Will Benefit from Avastin
Determining Which Bowel Cancer Patients Will Benefit From Avastin
Source: Colorectal Cancer ,25 Oct 2012
“Avastin, or Bevacizumab, has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit.
Avastin works by targeting and blocking the VEGF-A protein, two major forms of which are VEGF165 and VEGF165b.”
Source: Colorectal Cancer
Source: Colorectal Cancer ,25 Oct 2012
“Avastin, or Bevacizumab, has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit.
Avastin works by targeting and blocking the VEGF-A protein, two major forms of which are VEGF165 and VEGF165b.”
Source: Colorectal Cancer
Protein Levels May Predict if Patients Benefit from Avastin
Protein levels could predict if bowel cancer patients will benefit from Avastin
Source: University of Bristol 23 October 2012
“Comparing levels of specific proteins that the drug Avastin targets could identify patients with advanced bowel cancer who will benefit from the treatment, according to research published in Clinical Cancer Research* (Tuesday 23 October).
Avastin, or Bevacizumab, has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit.
Avastin works by targeting and blocking the VEGF-A protein, two major forms of which are VEGF165 and VEGF165b.
VEGF165 helps cancers to grow new blood vessels, so they can get food and oxygen from the blood - all cancers need a blood supply to be able to survive and grow. Its sister protein, VEGF165b, has the opposite effect and acts as a brake on this growth.”
Source: University of Bristol News
FDA Announces Avastin Counterfeit
FDA Issues Letters Advising of Counterfeit
Avastin is an injectable medicine used to treat cancer. It is administered to patients in clinics, hospitals, and doctors' offices. Roche manufactures Avastin approved for marketing outside of the United States.
On February 14, 2012, the FDA announced Roche conducted laboratory tests confirming a counterfeit version of Avastin. The counterfeit version does not include bevacizumab, the active ingredient necessary in Avastin.
To date, nineteen medical practices in the Unites States have been identified as having purchase the counterfeit version of "Avastin" from a foreign supplier.
Packages or vials may be counterfeit if they:
are labeled with Roche as the manufacturer
display batch numbers that start with B6010, B6011 or B86017.
The only FDA-approved version of Avastin for use in the United States is marketed by Genentech (a member company of Roche).
The FDA-approved version does not include the Roche logo on the packaging or vials.
Click here for detailed article from FDA
Source: FDA 02.14.12
Avastin is an injectable medicine used to treat cancer. It is administered to patients in clinics, hospitals, and doctors' offices. Roche manufactures Avastin approved for marketing outside of the United States.
On February 14, 2012, the FDA announced Roche conducted laboratory tests confirming a counterfeit version of Avastin. The counterfeit version does not include bevacizumab, the active ingredient necessary in Avastin.
To date, nineteen medical practices in the Unites States have been identified as having purchase the counterfeit version of "Avastin" from a foreign supplier.
Packages or vials may be counterfeit if they:
are labeled with Roche as the manufacturer
display batch numbers that start with B6010, B6011 or B86017.
The only FDA-approved version of Avastin for use in the United States is marketed by Genentech (a member company of Roche).
The FDA-approved version does not include the Roche logo on the packaging or vials.
Click here for detailed article from FDA
Source: FDA 02.14.12
Avastin Counterfeit
Counterfeit drugs: a growing global threat
Source: The Lancet, Volume 379, Issue 9817, Page 685, 25 February 2012
" The counterfeit drug trade has reached global proportions, and solving the problem needs a global approach..."
Click here for the entire article
Source: The Lancet, Volume 379, Issue 9817, Page 685, 25 February 2012
" The counterfeit drug trade has reached global proportions, and solving the problem needs a global approach..."
Click here for the entire article
Avastin Articles
Avastin (Bevacizumab)
Avastin: Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet goals
Source: Roche, Feb 2010
Bevacizumab + Xeliri* an effective alternative to Avastin+5 FU+Leucovorin+Folfiri for metastatic Colorectal Cancer
Source: ESMO-GI, July 2009
Avastin and Xeloda Treatment for Pseudomyxoma Peritonei and Appendix Cancer
Source: Cancer Bio Ther Austria and China, Aug 2009
Cetuximab (Erbitux)
Cetuximab (Erbitux) may not improve survival rates for stage III colon cancer cases
Adding Cetuximab to FOLFOX does not improve survival in advanced colon cancers
Source: HemoOnc June 10, 2010
EFGR Study for Colorectal Cancer: Resistance to Cetuximab and Panitumumab
Source: Journal of Clinical Oncology March 2010
Cetuximab for Liver Mets from Colorectal Cancer
Rectal Cancer Response to Cetuximab
(April 2009)
Cetuximab, Defined
Source: National Cancer Institute, 2009
KRAS mutant status helps predict survival for Colorectal Cancer patients treated with Cetuximab, Folifiri, Folfox 6
Source: ESMO GI, June 2009
Erbitux
Erbitux Use for Colon Cancer
Erbitux Q and A
Chemotherapy, General Info
General Chemotherapy Descriptions
Chemotherapy, General Guide
CenterWatch Clinical Trials Notification Service
Folfox
PMP Pals Share Solutions for Coping with Folfox Chemotherapy
PMP Pals Share Solutions for Coping with Folfox Chemotherapy
This week’s conversations in the Pals’ Chemo Resource & Support Group focuses on combatting the side effects of systemic chemotherapy.
Our Pal, Karen, USA, is experiencing challenges with digestive distress (nausea, vomiting and dehydration) as side effects from Folfox. Her Pal Mentors offer the following suggestions:
Joanne from the USA suggests:
I received my chemotherapy treatments from Wednesdays through Fridays and didn’t feel nauseated until the weekends, at which time I took Compazine, Emend, Zofran and Ativan. I used the weekends to recuperate and to sleep and would return to work, refreshed, each Monday.”
Carol from the USA suggests:
I experienced serious bouts of nausea and vomiting during the days immediately following my Folfox treatments. Therefore, my oncologist prescribed a combo of Ondansetron, Lorazepam, Dexamethasone and Prochlorerazine, to be taken at specific times throughout the course of the day. This helped tremendously and I ceased to experience the side effects.”
Mark from the USA suggests:
I worked an 8 hour day while on chemotherapy. When I was receiving Folfox I used Zofran during the day and took Lorazepam at night. A couple of times during my treatment had to go in for an IV treatment to stop the nausea. I kept the medication with me and tried to take it whenever I felt nauseous. I found it helpful to eat small snacks and meals of bland food throughout the day, to control the nauseas.
Robert from the USA suggests:
“Zofran works for me (to combat nausea. Otherwise, I eat minimally when I have a queasy stomach. I use a heating pad on my stomach, and curl up, take a nap, and let the uncomfortable feelings pass. I also chew on “Tums” which also help!”
Visit www.pmppals.org to learn more about Folfox and other chemotherapies. and to sign up for your own Pal Mentor!
Articles posted in PMP Pals and on www.pmppals.org are written from the perspective of patients and their family caregivers and are not intended to substitute for licensed, professional legal or medical advice. Individual should seek counsel from licensed professionals regarding their specific needs. Copyright © 2012 by PMP Pals' Network/All rights reserved. Visit us on the web at www.pmppals.org
This week’s conversations in the Pals’ Chemo Resource & Support Group focuses on combatting the side effects of systemic chemotherapy.
Our Pal, Karen, USA, is experiencing challenges with digestive distress (nausea, vomiting and dehydration) as side effects from Folfox. Her Pal Mentors offer the following suggestions:
Joanne from the USA suggests:
I received my chemotherapy treatments from Wednesdays through Fridays and didn’t feel nauseated until the weekends, at which time I took Compazine, Emend, Zofran and Ativan. I used the weekends to recuperate and to sleep and would return to work, refreshed, each Monday.”
Carol from the USA suggests:
I experienced serious bouts of nausea and vomiting during the days immediately following my Folfox treatments. Therefore, my oncologist prescribed a combo of Ondansetron, Lorazepam, Dexamethasone and Prochlorerazine, to be taken at specific times throughout the course of the day. This helped tremendously and I ceased to experience the side effects.”
Mark from the USA suggests:
I worked an 8 hour day while on chemotherapy. When I was receiving Folfox I used Zofran during the day and took Lorazepam at night. A couple of times during my treatment had to go in for an IV treatment to stop the nausea. I kept the medication with me and tried to take it whenever I felt nauseous. I found it helpful to eat small snacks and meals of bland food throughout the day, to control the nauseas.
Robert from the USA suggests:
“Zofran works for me (to combat nausea. Otherwise, I eat minimally when I have a queasy stomach. I use a heating pad on my stomach, and curl up, take a nap, and let the uncomfortable feelings pass. I also chew on “Tums” which also help!”
Visit www.pmppals.org to learn more about Folfox and other chemotherapies. and to sign up for your own Pal Mentor!
Articles posted in PMP Pals and on www.pmppals.org are written from the perspective of patients and their family caregivers and are not intended to substitute for licensed, professional legal or medical advice. Individual should seek counsel from licensed professionals regarding their specific needs. Copyright © 2012 by PMP Pals' Network/All rights reserved. Visit us on the web at www.pmppals.org
Folfox Folfiri
Taste Disorders Associated with Folfox Folfiri Affect Quality of Life
Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer
Takimoto N, Sugawara S, Iida A, Sakakibara T, Mori K, Sugiura M, Yamamura K, Adachi M.
Source: Dept. of Pharmacy, Kariya Toyota General Hospital. March 2009
Abstract
Taste disorders are frequent occurrences among those patients under the FOLFOX-FOLFIRI regimen for colorectal cancer.
We conducted a study on the development of taste disorders among colorectal cancer patients under this regimen and the effect of such disorders on their QOL. Taste disorders occurred in 58.1%(18/31 cases)of these patients and the disorders affected appetites in 50%(9 cases).
The changes in taste sensations were subtle in most but some described certain tastes as exaggerated. Others reported changes in all taste sensations, including sweet, salty, bitter and sour, as well as deliciousness.
When tested via the QOL Survey Sheet(Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs: QOL-ACD), the QOL was found to have deteriorated significantly in those who stated that taste disorders affected their appetite, in comparison with those who were unaffected. In patients with colorectal cancers and treated with the FOLFOX-FOLFIRI regimen, taste disorders are frequent occurrences.
The poor nutritional state due to a loss of appetite may constitute a factor responsible for a lowering QOL.
PMID: 19295267 [PubMed - indexed for MEDLINE]
Takimoto N, Sugawara S, Iida A, Sakakibara T, Mori K, Sugiura M, Yamamura K, Adachi M.
Source: Dept. of Pharmacy, Kariya Toyota General Hospital. March 2009
Abstract
Taste disorders are frequent occurrences among those patients under the FOLFOX-FOLFIRI regimen for colorectal cancer.
We conducted a study on the development of taste disorders among colorectal cancer patients under this regimen and the effect of such disorders on their QOL. Taste disorders occurred in 58.1%(18/31 cases)of these patients and the disorders affected appetites in 50%(9 cases).
The changes in taste sensations were subtle in most but some described certain tastes as exaggerated. Others reported changes in all taste sensations, including sweet, salty, bitter and sour, as well as deliciousness.
When tested via the QOL Survey Sheet(Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs: QOL-ACD), the QOL was found to have deteriorated significantly in those who stated that taste disorders affected their appetite, in comparison with those who were unaffected. In patients with colorectal cancers and treated with the FOLFOX-FOLFIRI regimen, taste disorders are frequent occurrences.
The poor nutritional state due to a loss of appetite may constitute a factor responsible for a lowering QOL.
PMID: 19295267 [PubMed - indexed for MEDLINE]
Erbitux, Folfox, Folfiri
Cetuximab (Erbitux) may not improve survival rates for stage III colon cancer cases
Adding Cetuximab to FOLFOX does not improve survival in advanced colon cancers
Source: HemoOnc June 10, 2010
FolfoxFolfiri
FolfiriFolfiri:metastatic gastric cancer
Source: ASCO 2009
Folfox/Folfiri in lieu of surgery for advanced stage Colorectal Cancer
Source: ASCO 2009
Folfox and Folfiri for metastatic colorectal cancer
Source: Clinical Colorectal Cancer 2005
Folfiri: Systemic Chemotherapy for the Treatment of Pseudomyxoma Peritonei, Mucinous Adenocarcinoma
KRAS mutant status helps predict survival of Colorectal Cancer pts treated w/Cetuximab, Folifiri, Folfox 6
Source: ESMO GI, June 2009
Folfox and Folfiri Phase II Study for Peritoneal Carcinomatosis Professor P Piso, in Regensburg, Germany provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis.
For more information, contact:
Prof. Dr. P. Piso
Leitender Oberarzt
Klinik und Poliklinik für Chirurgie
der UniversitätRegensburg
Franz Josef Strauß Allee 11
D-93053 Regensburg
Tel.: 0941-944-6809
Fax: 0941-944-6860
Quality of Life Study
Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
Source:
1. *Correspondence to: Mrs H. Gilet, Mapi Consultancy, 27 rue de la Villette, 69003 Lyon, France. Tel: +33-4-72-13-59-78; Fax: +33-4-72-13-51-40; E-mail: hgilet@mapigroup.com
2. © Copyright Oxford Journals Annals of Oncology Volume 23 Issue I pp 1979-1985
Background Malignant ascites (MA) is associated with poor prognosis and limited palliative therapeutic options. Therefore, quality of life (QoL) assessment is of particular importance to demonstrate new treatment value. Following the demonstration of the superiority of catumaxomab and paracentesis over paracentesis on puncture-free survival, this analysis aimed at comparing deterioration in QoL between both the treatment options.
Conclusions Treatment with catumaxomab delayed deterioration in QoL in patients with MA. Compared with paracentesis alone, catumaxomab enabled patients to benefit from better QoL for a prolonged survival period.
Read entire article >>>
Q&A About Appendix Cancer Chemotherapy
Ken on chemo!
What is appendix cancer chemotherapy?
What type of chemotherapy is prescribed for appendiceal cancer?
Is chemotherapy necessary for the treatment of appendix cancer?
Become a "Pal" and begin participating in our "Chemo Pals Resource & Support Group today!
Here are a variety of informative websites and articles, for your review:
Questions to Ask Your Oncologist About Chemotherapy
Source: National Institutes of Health
Assay Testing, Cell Based Oncology Assays
Exigon Diagnostics (formerly Oncotech)
Source: Exigon
Catumaxomab (Removab)
Source: NCI
Catumaxomab: Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Source NIH: January 2009
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Source: NIH 2008
Cisplatin
Effects of Cisplatin Exposure
Source: Elsevier 2008
Cisplatin Side Effects
Source: Journal of Clinical Oncology 1986
IP Cisplation Treatment for Peritoneal Carcinomatosis of the Ovaries
Combrestatin
Combrestatin
EFGR
EFGR Study for Colorectal Cancer: Resistance to Cetuximab and Panitumumab
Source: Journal of Clinical Oncology March 2010
Biomarkers Predict Outcome of EFGR Targeted Therapy Colorectal Cancers
Source: Journal of the National Cancer Inst, 2009
EFGR definition
Source: NCI
Eloxatin (see also Oxaliplatin)
Eloxatin Approved for Colorectal Cancer
Eloxatin Information Site
Flourouracil
Flourouracil
Gastric Cancer
Gastric Cancer Survival Rates increase with Chemotherapy
Source: JAMA, May 2010
HIPEC
Herception
Herceptin use for Gastric Cancer
Source: ASCO 45th Annual Meeting Report,2009
Iressa
Iressa Clinical Trials
Iressa Studies and Trials
Irinotecan
Irinotecan with 5 FU
KRAS Mutation Testing
Listing of laboratories for KRAS mutation testing
Exigon Diagnostics (formerly Oncotech)
Source: Exigon
Leucovorin
Leucovorin
Mitomycin
Mitomycin
Oxaliplatin
Oxaliplation (see also Eloxatin)
Source: Sanofi Aventis
Oxaliplatin
Sulindac
Sulindac (Clinoril)
Tarceva
Tarceva or Erlotinib
Tacotere
Taxotere (Docetaxel) Use for Stomach Cancer
Xeliri*
Capetcitabine + Irinotecan
Xelox
Xelox (Capecitabine + Oxaliplatin)
Source: Journal of Clinical Oncology, 2004
Isolated Perfusion of Chemotherapy
Regional Chemotherapy via Isolated Perfusion for Cisplatin Resistant Ovarian Cancer
Source: Professor Karl Aigner, Germany 2008
Profile of Prof Karl Aigner
Prof Karl Aigner describes regional perfusion at his clinic in Bavaria via video en espanol
Can inhibition of angiogenesis inhibitors result in tumor invasion and metastasis?
Source: Nature Review June 2009
"Chemo Brain": Is it real?
Source: New York Times, Jane Brody, August 2009
Maintenance Chemotherapy
Source: New York Times, July 2009
Suggestions for coping w/"Chemo Brain"
Source: New York Times, Jane E Brody, August 2009
Anti Nausea Medications
Emend (Aprepitant)
Source: Merck
Colorectal Cancer Care
Dr Cathy Eng, Oncologist, MD Anderson, Houston TX
Source: MD Anderson
Refer to the Clinical Trials page for additional information about Chemotherapy options.
Advanced Cancers Destined to Recur After Treatment with Single Drugs
Advanced Cancers Destined to Recur After Treatment with Single Drugs
Source: 06/12/2012
“Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.
In a study of 28 advanced colon cancer patients treated with the monoclonal antibody panitumumab, the Johns Hopkins Kimmel Cancer Center team reports that drug-resistance tumor cell mutations appear in the blood of patients five to seven months later, and that low levels of these mutations exist in nearly all tumors before the therapy begins, making the cancers predestined to recur.” © Johns Hopkins
Source: 06/12/2012
“Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.
In a study of 28 advanced colon cancer patients treated with the monoclonal antibody panitumumab, the Johns Hopkins Kimmel Cancer Center team reports that drug-resistance tumor cell mutations appear in the blood of patients five to seven months later, and that low levels of these mutations exist in nearly all tumors before the therapy begins, making the cancers predestined to recur.” © Johns Hopkins
Effect of Aspirin on Cancer Metastasis
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
Prof Peter M Rothwell FMedSci, Michelle Wilson MSc a, Jacqueline F Price MD b, Prof Jill FF Belch MD c, Prof Tom W MeadeFRS d, Ziyah Mehta PhD a
Background:Daily aspirin reduces the long-term incidence of some adenocarcinomas, but effects on mortality due to some cancers appear after only a few years, suggesting that it might also reduce growth or metastasis. We established the frequency of distant metastasis in patients who developed cancer during trials of daily aspirin versus control.
Methods: Our analysis included all five large randomised trials of daily aspirin (≥75 mg daily) versus control for the prevention of vascular events in the UK. Electronic and paper records were reviewed for all patients with incident cancer. The effect of aspirin on risk of metastases at presentation or on subsequent follow-up (including post-trial follow-up of in-trial cancers) was stratified by tumour histology (adenocarcinoma vs other) and clinical characteristics.
Findings: Of 17 285 trial participants, 987 had a new solid cancer diagnosed during mean in-trial follow-up of 6·5 years (SD 2·0). Allocation to aspirin reduced risk of cancer with distant metastasis (all cancers, hazard ratio [HR] 0·64, 95% CI 0·48—0·84, p=0·001; adenocarcinoma, HR 0·54, 95% CI 0·38—0·77, p=0·0007; other solid cancers, HR 0·82, 95% CI 0·53—1·28, p=0·39), due mainly to a reduction in proportion of adenocarcinomas that had metastatic versus local disease (odds ratio 0·52, 95% CI 0·35—0·75, p=0·0006). Aspirin reduced risk of adenocarcinoma with metastasis at initial diagnosis (HR 0·69, 95% CI 0·50—0·95, p=0·02) and risk of metastasis on subsequent follow-up in patients without metastasis initially (HR 0·45, 95% CI 0·28—0·72, p=0·0009), particularly in patients with colorectal cancer (HR 0·26, 95% CI 0·11—0·57, p=0·0008) and in patients who remained on trial treatment up to or after diagnosis (HR 0·31, 95% CI 0·15—0·62, p=0·0009).
Allocation to aspirin reduced death due to cancer in patients who developed adenocarcinoma, particularly in those without metastasis at diagnosis (HR 0·50, 95% CI 0·34—0·74, p=0·0006). Consequently, aspirin reduced the overall risk of fatal adenocarcinoma in the trial populations (HR 0·65, 95% CI 0·53—0·82, p=0·0002), but not the risk of other fatal cancers (HR 1·06, 95% CI 0·84—1·32, p=0·64; difference, p=0·003).
Effects were independent of age and sex, but absolute benefit was greatest in smokers. A low-dose, slow-release formulation of aspirin designed to inhibit platelets but to have little systemic bioavailability was as effective as higher doses.
Interpretation: That aspirin prevents distant metastasis could account for the early reduction in cancer deaths in trials of daily aspirin versus control. This finding suggests that aspirin might help in treatment of some cancers and provides proof of principle for pharmacological intervention specifically to prevent distant metastasis.
Funding:None.
Source: The Lancet, Early Online Publication, 21 March 2012, doi:10.1016/S0140-6736(12)60209-8Cite or Link Using DOI
Prof Peter M Rothwell FMedSci, Michelle Wilson MSc a, Jacqueline F Price MD b, Prof Jill FF Belch MD c, Prof Tom W MeadeFRS d, Ziyah Mehta PhD a
Background:Daily aspirin reduces the long-term incidence of some adenocarcinomas, but effects on mortality due to some cancers appear after only a few years, suggesting that it might also reduce growth or metastasis. We established the frequency of distant metastasis in patients who developed cancer during trials of daily aspirin versus control.
Methods: Our analysis included all five large randomised trials of daily aspirin (≥75 mg daily) versus control for the prevention of vascular events in the UK. Electronic and paper records were reviewed for all patients with incident cancer. The effect of aspirin on risk of metastases at presentation or on subsequent follow-up (including post-trial follow-up of in-trial cancers) was stratified by tumour histology (adenocarcinoma vs other) and clinical characteristics.
Findings: Of 17 285 trial participants, 987 had a new solid cancer diagnosed during mean in-trial follow-up of 6·5 years (SD 2·0). Allocation to aspirin reduced risk of cancer with distant metastasis (all cancers, hazard ratio [HR] 0·64, 95% CI 0·48—0·84, p=0·001; adenocarcinoma, HR 0·54, 95% CI 0·38—0·77, p=0·0007; other solid cancers, HR 0·82, 95% CI 0·53—1·28, p=0·39), due mainly to a reduction in proportion of adenocarcinomas that had metastatic versus local disease (odds ratio 0·52, 95% CI 0·35—0·75, p=0·0006). Aspirin reduced risk of adenocarcinoma with metastasis at initial diagnosis (HR 0·69, 95% CI 0·50—0·95, p=0·02) and risk of metastasis on subsequent follow-up in patients without metastasis initially (HR 0·45, 95% CI 0·28—0·72, p=0·0009), particularly in patients with colorectal cancer (HR 0·26, 95% CI 0·11—0·57, p=0·0008) and in patients who remained on trial treatment up to or after diagnosis (HR 0·31, 95% CI 0·15—0·62, p=0·0009).
Allocation to aspirin reduced death due to cancer in patients who developed adenocarcinoma, particularly in those without metastasis at diagnosis (HR 0·50, 95% CI 0·34—0·74, p=0·0006). Consequently, aspirin reduced the overall risk of fatal adenocarcinoma in the trial populations (HR 0·65, 95% CI 0·53—0·82, p=0·0002), but not the risk of other fatal cancers (HR 1·06, 95% CI 0·84—1·32, p=0·64; difference, p=0·003).
Effects were independent of age and sex, but absolute benefit was greatest in smokers. A low-dose, slow-release formulation of aspirin designed to inhibit platelets but to have little systemic bioavailability was as effective as higher doses.
Interpretation: That aspirin prevents distant metastasis could account for the early reduction in cancer deaths in trials of daily aspirin versus control. This finding suggests that aspirin might help in treatment of some cancers and provides proof of principle for pharmacological intervention specifically to prevent distant metastasis.
Funding:None.
Source: The Lancet, Early Online Publication, 21 March 2012, doi:10.1016/S0140-6736(12)60209-8Cite or Link Using DOI
5 FU
Appendix Cancer Patient Affected by 5 FU Shortage
Are chemotherapies being hoarded for profit?
This video news report featuring an American appendix cancer patient, is preceeded by a brief advertisement.
Source: CBS News 10.13.11
This video news report featuring an American appendix cancer patient, is preceeded by a brief advertisement.
Source: CBS News 10.13.11
5 Flourourcil (5-FU) Shortage
American Society of Health Systems Pharmacists lists shortages of 5 FU
Source: ASHSP
Additional chemotherapies affected by the shortage:
Capecitabine Tablets (Xeloda)
• Cisplatin Injection
• Doxorubicin Injection
• Irinotecan Injection
• Mitomycin Injection
• Paclitaxel Injection
Source: ASHSP
Additional chemotherapies affected by the shortage:
Capecitabine Tablets (Xeloda)
• Cisplatin Injection
• Doxorubicin Injection
• Irinotecan Injection
• Mitomycin Injection
• Paclitaxel Injection
FDA Lists Drug Shortages
FDA
FDA Toll free number: 1.FDA.1088
Poison Control
American Association of Poison Control Centers Toll free number: 1.800.222.1222
This page is sponsored by Chris and Sherry, USA
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
The PMP Pals' Network updates our website 364 days per year with a wide variety of new information to keep you informed about maintaining optimal health! Whether you seek information about research studies, health insurance, personal mentoring, diet and exercise, new treatment options, and so much more, the PMP Pals' Network is your "go to" place for information! This page last updated on 05.20.13